Introduction {#S0001}
============

Intramedullary spinal cord metastases (ISCM) is rarely encountered in the clinical setting, and easily ignored by clinicians, owing to a lack of awareness and related research[@CIT0001]--[@CIT0011] ([Table 1](#T0001){ref-type="table"}). In fact, as the diagnosis and treatment of cancer improve and more cancer patients survive, the incidence of ISCM keeps rising. ISCM is often associated with rapid deterioration of neurological function and devastating outcome. Prompt identification and appropriate intervention is urgent to prevent neurological deficits and prolong patients' survival.[@CIT0012] Therefore, we carried out this retrospective research of ISCM, aiming to clarify the clinicopathological features and explore the optimal management of this special entity.Table 1Summary of prior studies of ISCM treatment and outcomeReferencesDateNumber of ptsSexMedian age (years)Primary tumorLocation of ISCMPresence of other metastasesTreatment strategyOutcome of neurological status post managementOverall median survival (range)(days)MaleFemaleCervicalThoracicLumbar to ConusBrainOther systemicImprovedUnchangedDeterioratedSung et al[@CIT0001]201330114311656 (4--82)Lung 144 (47.8%)122 (41%)102 (34%)113 (38%)n=214n=198Surgery 89 (40%)51 (33%)66 (43%)36 (24%)120 (4--1800)Breast 48 (15.9%)131 (61%)127 (64%)Surgery 36Surgery 19Surgery 7SurgeryMelanoma 18 (5.9%)Conservative treatment 107 (48%)Conservative treatment 15Conservative treatment 45Conservative treatment 12180 (14--720)Renal cell 17 (5.6%)Palliative treatmentPalliative treatment 0Palliative treatment 2Palliative treatment 17Conservative treatmentColorectal 16 (5.3%)27 (12%)150 (14--1800)Lymphoma 14 (4.7%)Palliative treatmentCNS (drop metastasis) 11 (3.7%)30 (4--120)Unknown 10 (3.3%)Sarcoma 6 (2.0%)Ovarian 5 (1.7%)Endometrial 2 (0.7%)Esophageal 2 (0.7%)Gastric 2 (0.7%)Others 6 (2.0%)Dam-Hieu et al[@CIT0002]20091910956 (35--75)Lung 13 (68%)4 (21%)5 (26.3%)11 (58%)5 (26.3%)55 (26.3%)Surgery 13 (68%)9 (52.6%)7 (36.8%)3 (15.8%)183 (4−720)Breast 3 (16%)Radiotherapy 11 (57.9%)Surgery+Radiotherapy 9Surgery 2Surgery 3Colorectal 1 (5.5%)Chemotherapy 1 (5.2%)Chemotherapy 0Radiotherapy 0Radiotherapy 0Esophageal 1 (5.5%)Abstention 5 (26.3%)Abstention 0Chemotherapy 1Chemotherapy 0Thyroid carcinoma 1 (5.5%)Abstention 4Abstention 0Shin et al[@CIT0003]200993650 (14--71)Lung 2 (22.2%)6 (66.7%)2 (22.2%)2 (22.2%)8 (88.9%)2 (22.2%)Radiosurgery 9811240 (60--570)Breast 3 (33.3%)Renal cell carcinoma 1 (11.1%)Melanoma 1 (11.1%)Choroid plexus carcinoma 1 (11.1%)Glioma 1 (11.1%)Flanagan et al[@CIT0004]201275261 (41--81)non-Hodgkin's lymphoma 7 (100%)4 (57.1%)4 (57.1%)0NANARadiotherapy 16 (100%)00345 (30--840)Chemotherapy 3\
Chemotherapy + Radiotherapy 2Unknown 1Hashii et al[@CIT0005]20111881055 (37--76)Lung 8 (44.4%)NANANA14 (77.8%)NARadiotherapy8 (44.4%)10 (55.6%)0120Breast 6 (33.3%)Melanoma 2 (11.1%)Renal cell carcinoma 1 (5.6%)Rectal cancer 1 (5.6%)Veeravagu et al[@CIT0006]201294563 (33--77)Lung 2 (22.2%)7 (77.8%)3 (33.3%)1 (11.1%)NANARadiosurgery1 (20%)4 (80%)0123 (33--273)Breast 5 (55.6%)Cystic adenocarcinoma 1 (11.1%)Epithelioid hemangioepithelioma 1 (11.1%)Wilson et al[@CIT0007]201293656 (38--68)Lung 3 (33.3%)4 (44.4%)5 (55.6%)0NANASurgery1 (11.1%)7 (77.8%)1 (11.1%)192Breast 4 (44.4%)Melanoma 2 (22.2%)Hoover et al[@CIT0008]2012159655 (38--74)Lung 1 (6.7%)3 (20%)2 (13%)10 (67%)3 (20%)NASurgery8 (53.3%)2 (13.3%)5 (33.3%)150Breast 2 (13.3%)Melanoma 3 (20%)Renal cell carcinoma 3 (20%)Carcinoid tumor 1 (6.7%)Mesenchymal chondrosarcoma 2 (13.3%)Gastric adenocarcinoma 1 (6.7%)Chondrosarcoma 1 (6.7%)Diffuse large B-cell lymphoma 1 (6.7%)Diehn et al[@CIT0009]; Rykken et al[@CIT0010]201549232657.7 (7--80)Lung carcinoma 24 (49%)18 (26%)40 (57%)12 (17%)NANANANANANA104 (95% CI=48--156)Breast carcinoma 7 (14%)Melanoma 5 (10%)CNS origin 4 (8%)Renal cell carcinoma 3 (6%)Other 6 (12%)Payer et al[@CIT0011]20152213955 (21--86)Lung carcinoma 6 (27.2%)9 (41%)14 (63.6%)5 (22.7%)9 (41%)6 (27.2%)Surgery 22 (100%)4 (21%)11 (58%)4 (21%)348Breast carcinoma 3 (13.6%)Surgery+Radiotherapy 6 (27.2%)Melanoma 2 (9%)Surgery+Chemotherapy 7 (31.8%)CNS origin 3 (13.6%)Surgery+RadiotherapyBladder carcinoma 1 (4.5%)+Chemotherapy 3 (13.6%)Prostate carcinoma 1 (4.5%)Ovarian carcinoma 1 (4.5%)Kidney carcinoma 1 (4.5%)Unknown 4 (18.1%)[^2]

Materials and methods {#S0002}
=====================

Study population {#S0002-S2001}
----------------

From June 2010 to March 2018, 61 patients diagnosed as ISCM with a history of malignancy in the First Hospital, Jilin University were retrospectively analyzed. All the patients had a definitive MRI manifestation of ISCM. Besides, four patients underwent surgery which confirmed ISCM pathologically. Only three individuals were lost to follow-up. Data were retrieved according to characteristics such as age, gender, primary pathology, diagnostic methods, interval from primary cancer to ISCM, performance status (PS) at diagnosis of ISCM, involved segment and number of spinal cord, synchronous metastasis, interventions, treatment response, outcomes, and overall survival (OS). OS was defined as the period from the diagnosis of ISCM to the death or latest follow-up. The end date for last follow-up was July 8, 2018.

Ethical considerations {#S0002-S2002}
----------------------

This study was approved by the Ethics Committee of the First Hospital of Jilin University (no 2018--358) and conducted in accordance with the Declaration of Helsinki. Patient consent to review their medical records was waived due to the retrospective nature of the study. Patient data were reviewed confidentially.

Statistical analysis {#S0002-S2003}
--------------------

The cumulative survival curve was generated by Kaplan-Meier method. Log-rank (Mantel-Cox) Test and Gehan-Breslow-Wilcoxon Test were used in univariate analysis of prognostic factors for OS. *P*\<0.05 was considered as statistically significant.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

Among the 61 ISCM patients enrolled in this review, there was no predominance of gender (M：F=1.03). The mean age at diagnosis of ISCM was 57.90 years (range=35--78 years). Lung cancer (67.21%) constituted the majority of primary malignancies. Additionally, small cell lung carcinoma (SCLC) (39.34%) was the most common subtype of lung cancer in ISCM. Other offenders with less frequencies included breast cancer (14.75%), prostate cancer (4.92%), liver cancer (3.28%), diffuse large B-cell lymphoma (DLBCL, 3.28%), colon cancer (1.64%), retal cancer (1.64%), ovarian cancer (1.64%), and endometrial carcinoma (1.64%) ([Figure 1](#F0001){ref-type="fig"}). All the patients had definite MRI findings suggestive of ISCM. Four patients conducted local resection which confirmed ISCM pathologically besides the typical MRI manifestation of spinal cord parenchymal involvement. Notably, in six individuals, ISCM was the first sign of primary cancer outside the central nervous system (CNS). The mean interval from primary cancer developed to ISCM was 18.77 months (range=0--10 years). Generally, patients of ISCM had a poor physical function. Over half of individuals (55.74%) had a PS score of 3 or 4. Twenty-six patients developed into complete paraplegia, and the average interval to paraplegia was 22.85 days. At the diagnosis of ISCM, in terms of the control of primary cancer, 20 and 28 patients were evaluated as progressive disease (PD) and stable disease (SD), respectively. Eight candidates underwent complete resection of the primaries ([Table 2](#T0002){ref-type="table"}). Table 2Clinical features of ISCM patientsn%Sex (n=61)Male3150.82Female3049.18Age (years) (n=61)Mean at diagnosis of ISCM (years)57.90Range (years)35-78Primary Cancer Pathology (n=61)Lung cancer4167.21  SCLC2439.34  Lung adenocarcinoma813.11  Lung squamous carcinoma11.64  Lung large cell carcinoma11.64  Lung poorly differentiated adenocarcinoma with neuroendocrine carcinoma11.64  NSCLC11.64  Not specified58.20Breast Cancer914.75Prostate Cancer34.92Liver Cancer23.28DLBCL23.28Colon Cancer11.64Retal Cancer11.64Ovarian cancer11.64Endometrial carcinoma11.64MRI (n=61)Yes61100No00ISCM pathology (n=61)Yes (surgery)46.56No5793.44Interval from primary cancer to ISCM (n=61)At diagnosis of primary cancer69.84Mean (months)18.77Range (years)0-10PS at diagnosis of ISCM-ECOG (n=61)011.6411321.3121321.3132134.4341321.31Occurrence of paraplegia (n=60)Yes2643.33No3456.67Speed until paraplegia (n=26)Average interval to paraplegia (day)22.85Control of the primary cancer at the diagnosis of ISCM (n=58)PD2034.48SD2848.28PR or CR23.45CR (complete resection)813.79[^3] Figure 1Histologic types of primary cancer in the development of ISCM (n=61).**Abbreviation:** ISCM, intramedullary spinal cord metastases.

In terms of the involved spinal cord segments of ISCM, the thoracic segment was most common (77.05%), followed by cervical (39.34%), lumbar level (34.43%), and conus medullaris (6.56%) ([Table 3](#T0003){ref-type="table"}). In total, 55.74% patients involved one spinal cord level among C/T/L/Conus medullaris, while 32.79% individuals had two levels of ISCM, 9.84% patients had three levels of involvement, while only one patient (1.64%) had whole spinal cord involvement ([Figure 2](#F0002){ref-type="fig"}). Table 3Involved spinal cord segments of ISCM patients (n=61)Involved spinal cord segmentsn%C2439.34T4777.05L2134.43Conus medullaris46.56[^4] Figure 2The number of involved spinal cord segments at the diagnosis of ISCM (n=61).**Abbreviation:** ISCM, intramedullary spinal cord metastases.

Synchronous metastases in other organs or tissues of ISCM patients were found in 58 patients. Bone was the most common metastatic sites concurrently (75.86%), followed by brain (62.07%), leptomeninges (24.14%), liver (17.24%), adrenal gland (12.07%), lung (5.17%), kidney (3.45%), marrow (3.45%), muscle (3.45%), non-regional lymph node (3.45%), and spleen (1.72%) ([Table 4](#T0004){ref-type="table"}). Unsurprisingly, 72.41% patients had multiple metastases in other sites synchronously when diagnosed as ISCM (two organs: 41.38%; three organs: 22.41%; four organs: 8.62%), indicating ISCM was generally end-stage disease ([Figure 3](#F0003){ref-type="fig"}). Table 4Other synchronous metastatic sites of ISCM patients (n=58)Sites of metastasesn%Lung35.17Liver1017.24Bone4475.86Brain3662.07leptomeninges1424.14Adrenal gland712.07Kidney23.45Spleen11.72Marrow23.45Muscle23.45Non-regional lymph node23.45[^5] Figure 3The number of concurrent metastases in other organs at the diagnosis of ISCM (n=58).**Abbreviation:** ISCM, intramedullary spinal cord metastases.

Treatment {#S0003-S2002}
---------

After diagnosis of ISCM, 13 individuals refused any interventions, and the treatment information was unavailable in one patient. Due to the poor general status and heavy tumor burden, a small proportion of patients underwent surgery (8.51%), while 82.98% performed local irradiation, 36.17% undertook chemotherapy, and only one patient took Crizotinib for ALK gene rearrangement ([Table 5](#T0005){ref-type="table"}). As the first therapeutic option of ISCM, RT was essential for definite efficacy and acceptable toxicity. RT achieved an ORR of 61.90% or 62.50% and LCR of 90.48% or 87.50% for symptoms used singly or combined with other strategies, respectively ([Table 6](#T0006){ref-type="table"}). Only one patient underwent RT with 5 Gy in a single fraction. Thirty-six patients conducted conventional external beam RT with 1.8/2.0/2.5/3.0 Gy per fraction. Table 5Treatment strategies of the ISCM patients (n=47)n%SurgeryYes48.51No4391.49RadiotherapyYes3982.98No817.02ChemotherapyYes1736.17No3063.83Target therapyYes12.13No4697.87[^6] Table 6Evaluation for symptoms control by RT (n=37)nORR (%)LCR (%)RT2161.9090.48Complete remission2Improved11Unchanged6Deteriorated2Multiple modality including RT1662.5087.50RT+CT\
Improved8\
6Unchanged2RT+CT+nerve blocking1Improved1RT+IT4Improved2Unchanged1Deteriorated1RT+Crizotinib1Unchanged1RT+S+CT2Improved1Deteriorated1[^7]

Survival analysis {#S0003-S2003}
-----------------

ISCM patients usually bear a rather dismal prognosis. The median OS of ISCM was only 4 months ([Figure 4](#F0004){ref-type="fig"}). Figure 4Overall survival (OS) curve (n=58).

Gender and age were not prognostic factors of OS in ISCM patients (M: 4.0 vs F: 5.0 months; ≤55: 4.0 vs \>55: 4.0 months). The median OS for patients with a PS score of 0--2 was longer than its counterpart with a PS score 3--4 (5.0 vs 3.0 months) but failed to reach statistical difference. The median OS for candidates with one synchronous metastatic site appear to be better than those with 2--4 sites (5.5 vs 4.0 months), but didn't reach statistical difference. The number of involved spinal cord segments had a strong association with OS. Patients with only one segment involved (C/T/L/Conus medullaris) had an apparently better prognosis than those with two-to-four involved segments (median OS: 7.0 vs 3.0 months) (*P*\<0.01). The OS of patients treated was remarkably superior to those without any management (median OS: 5.0 vs 2.0 months) (*P*\<0.01) ([Table 7](#T0007){ref-type="table"}, [Figure 5](#F0005){ref-type="fig"}). Table 7Univariate analysis of prognostic factors for OSPrognostic factorHazard ratio\
(95% CI)*P*-value\
Log-rank\
(Mantel-Cox) test*P*-value\
Gehan-Breslow-Wilcoxon testGender (M: F)1.258 (0.7081--2.235)0.43380.2450Age (years) (≤55: \>55)1.055 (0.5666--1.963)0.86640.9522PS (0--2: 3--4)0.9207 (0.5171--1.639)0.77890.1220Number of concurrent metastases in other organs\
(1: 2--4)0.6413 (0.3473--1.184)0.15570.3649Number of involved spinal cord segments (1: 2--4)0.4199 (0.2254--0.7823)0.00630.0063Treatment (yes: no)0.1987 (0.06931--0.5697)0.00260.0024[^8] Figure 5Number of ISCM segments and treatment affect OS of ISCM while gender, age, PS and number of synchronous metastatic sites fail to show a defined correlation with OS.**Abbreviations:** ISCM, intramedullary spinal cord metastases; OS, overall survival; PS, performance status.

Discussion {#S0004}
==========

ISCM from malignancies is underestimated in clinical practice, especially in the pre-MRI era.[@CIT0013] With the increasing morbidity of cancer and the prolongation of patients' survival, the actual incidence of ISCM is rising. However, due to the relative low occurrence of ISCM and general setting of end-stage of cancer, no prospective studies have been conducted to date.[@CIT0013] As for the retrospective study, the largest research included 49 patients.[@CIT0009],[@CIT0010] Sung et al[@CIT0001] performed a 20-year retrospective study in the Royal Hobart Hospital of eight ISCM patients and reviewed 291 ISCM cases published in the literature since 1960. We conducted a review of related English literature with the key word "intramedullary spinal cord metastases" in Pubmed from June 2009 to January 2019, and found 10 case series of small samples.[@CIT0001]--[@CIT0011] The clinicopathological characteristics, managements, and subsequent outcomes of this special entity are summarized in [Table 1](#T0001){ref-type="table"}. To the best of our knowledge, our study is the largest single center research currently, and will help a lot to expand our understanding and aid practitioners in treatment of this unique situation.

Epidemiologically, in our research, ISCM occurred in a wide spectrum of patients, aged from 35 to 78 years, with a mean age at diagnosis of 57.90 years. ISCM was more likely to affect elderly individuals, similar to previous reports.[@CIT0001]--[@CIT0011],[@CIT0014] There was no predominance of gender, different from the male or female predominance described by other series.[@CIT0006],[@CIT0007],[@CIT0011],[@CIT0015],[@CIT0016] Notably, ISCM can herald an underlying neoplasm. 9.84% of patients presented with ISCM initially in our study, lower than the 18.75--25% reported previously.[@CIT0013],[@CIT0017],[@CIT0018] The interval from primary cancer to ISCM spanned up to 10 years, reminding clinicians of the possibility of ISCM in cancer populations presented with typical neurological deficits and MRI findings, even after a long latency. The thoracic segment appeared to be the most common involved (77.05%), similar to the reports by Diehn et al,[@CIT0009] Rykken et al[@CIT0010] and Payer et al.[@CIT0011] Rades and Schiff[@CIT0013] while Findlay et al[@CIT0019] found that the cervical segment was the most common site. Unsurprisingly, lung cancer was the main offender of ISCM, especially the subset of SCLC tending to have ISCM, followed by breast cancer, the same as previous reports.[@CIT0001],[@CIT0002],[@CIT0005],[@CIT0009],[@CIT0010] This might be partly explained by the fact that lung and breast cancer have the highest incidence with a large population.

Three possible routes have been posed for the occurrence of ISCM.[@CIT0020] Haematogeneous dissemination via arterial and/or venous pathways is considered as the main contributor. The coexistence of brain and lung (62.07% and 5.17% in our series,respectively) metastases confirmed spread by the arterial system. In the reports by Sung et al[@CIT0001] and Hashii et al,[@CIT0005] the brain metastasis coexisted in 61% and 77.8% of the cohort respectively. Leptomeningeal seeding via cerebrospinal fluid circulation is another vital mechanism. In our study, 24.14% of candidates coexisted with definite meningeal metastasis, supporting the above idea. Besides, the direct invasion from metastases of adjacent structures accounts for a considerable proportion of patients. Bone metastasis resulted in epidural spinal cord compression, then invaded through the dura and into the spinal cord parenchyma. Bone was the most common metastatic site concurrently (75.86%) in our report, suggesting direct invasion was an important route in ISCM.

Generally, ISCM patients bear an extremely grim outcome with a median OS of 4 months in our report, similar to 3--4 months by previous research.[@CIT0014],[@CIT0021] In the analyses summarized in [Table 1](#T0001){ref-type="table"}, the median OS of ISCM ranged from 104--348 days.[@CIT0001]--[@CIT0011] Therefore, the optimal intervention paradigm for ISCM has not been established.

RT has been proved to be critical in maintenance of quality-of-life (QoL) in ISCM individuals.[@CIT0005] However, for radioresistant tumors such as renal cell carcinoma and melanoma, conventional external RT (30 Gy in 10 fractions or 40 Gy in 20 fractions) is hard for ideal control of ISCM and relief of symptoms. Stereotactic radiosurgery (SRS) is promising for limited, oligometastatic disease.[@CIT0017] Parikh and Heron[@CIT0022] documented Cyberknife SRS (15 Gy in three fractions) contributed to a 26-month OS and nearly fully functional recovery in an ISCM patient of renal cell carcinoma. A retrospective research of nine patients with 11 ISCM conducted by Veeravagu et al[@CIT0006] noted that Cyberknife SRS delivered 14--27 Gy (median 21 Gy) in 1--5 fractions (median=3 fractions) was safe and effective. The neurological status post-management was improved and unchanged in 20% and 80% of patients, respectively.[@CIT0006] Garcia et al[@CIT0023] reported a dose of 14 Gy in one fraction to an ISCM lesion in a heavily-treated breast cancer patient who attained long-term local control of 37 months without obvious toxicity. The majority of patients in our research performed conventional fractionated RT with a single dose of 1.8/2.0/2.5/3.0 Gy and also gained satisfactory improvement of symptoms. This might be partly explained by the fact that radiosensitive tumors such as SCLC and breast cancer constituted the mainstay of the cohort.

For a long period, surgery has no role in the management of ISCM. With the development of intraoperative imaging guidance and microsurgical technique, surgery can exert a certain effect for the selective cohort. For those highly selected patients such as limited tumor burden, satisfactory PS and non-lymphoma primary, radical resection can bring OS benefit and neurological function improvement. In the document described by Sung et al,[@CIT0001] 36 out of 89 patients (40.45%) who underwent surgery attained improved neurological status. In the cohort presented by Payer et al,[@CIT0011] 22 ISCM patients performed surgery and gained the longest median OS of 348 days. The median OS was beyond 9.4 months in the surgery group vs 5 months in the conservative intervention group for ISCM.[@CIT0024] The surgery indication in ISCM should be highly selective, since the benefits and risks of surgery need to be fully evaluated. It had been reported that radical tumor resection of ISCM brought no survival benefits, but the deterioration of patients' function.[@CIT0025] However, in our retrospective research, surgery was unfeasible for the majority of patients, since 55.74% of the candidates had a poor physical status (PS=3--4), 44.26% had multiple involvements of spinal cord segments, and 72.41% of patients had widespread metastases in other sites synchronously when diagnosed as ISCM. Multimodal local intervention including surgery and irradiation might attain survival benefit. Minomo et al[@CIT0026] reported an ISCM patient of squamous cell lung cancer who experienced repeated recurrences, surgery, and radiotherapy twice contributed a long-term survival of 25 months.

Due to the existence of blood--spinal barrier, chemotherapy has little effect on the treatment of ISCM and failed to extend the survival for ISCM patients.[@CIT0024] Nowadays, chemotherapy is reserved for chemotherapy-sensitive tumors (such as small cell lung cancer and hematological neoplasms) and as an adjuvant therapy for radiotherapy or surgery.[@CIT0018]

For patients with rapidly developing spinal cord compression symptoms, steroid can quickly relieve pain and delay neurological deterioration by reducing local tissue edema and promoting the normality of the blood--spinal barrier without prolonging the patient's survival.[@CIT0024] Nowadays, for ISCM, the steroid is generally combined with other treatment strategies.[@CIT0018]

In the modern era of immunotherapy, checkpoint inhibitors shed new light for recurrent, refractory, and metastatic circumstances. Phillips et al[@CIT0027] documented regression of an ISCM with Nivolumab, an anti-programmed cell death-1 (PD-1) antibody in pulmonary adenocarcinoma. This dramatic response exerted by Nivolumab might be for tiny lesions such as 4 mm of ISCM described in the case mentioned above.[@CIT0027] Since the majority of ISCM is large with multiple segment involvements, the exact effect of checkpoint inhibitors is still unclear and needs to be further explored.

The treatment-related adverse events have been seldom reported previously, probably owing to the quite short survival of patients. Long-term adverse events, such as radiation myelitis, have not yet occurred in patients who have died. Further deterioration of neurological function postoperatively has been revealed by some studies, partly due to spinal cord edema and intraoperative nerve injury.[@CIT0001],[@CIT0002],[@CIT0008],[@CIT0011],[@CIT0025]

In terms of factors influencing therapeutic activity, ISCM originated from lung/breast carcinomas having a poorer survival than other pathological types. Besides, multiple ISCMs is also a worse prognostic indicator.[@CIT0009] Multiple spinal cord levels involvement and no treatment were unveiled to be poor prognostic factors of OS. Thus, early identification and active management is paramount for this unique entity. Multidisciplinary approach should be available and individualized according to the primary pathology, systemic spread of tumor, PS, and economic status of patient.

Conclusion {#S0005}
==========

ISCM is a special entity needing more attention with increasing incidence and still grim prognosis. Early diagnosis and multidisciplinary approach are critical for a better outcome. RT remains the mainstay of management nowadays. In the near future, multicentral or even national data is needed to clarify the clinicopathological features, prognostic factors, and optimal intervention for this unique disease.
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